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GAGslvement of the putative heparan sulfate proteoglycans (HSPG) binding motif,
KKTK, in mediating HAdV-5 liver cell infection following intravascular virus delivery has been debated. In the
present study, we demonstrated that HSPGs were not involved in the in vitro infection process of an
adenoviral vector harboring chimeric ﬁbers without mutation in the KKTK motif, HAdV-5-F2/BAdV-4. The
entry of HAdV-5-F2/BAdV-4 into cells occurs by two mechanisms 1) the attachment of HAdV-5-F2/BAdV-4 to
the surface of cells requires N-glycosylation, 2) the uptake of the virus is effective after interaction with a co-
receptor, putatively the chondroitin sulfate C. Together, these results contribute to improving our
understanding of the molecular mechanisms determining HAdV's infectivity in vitro and may aid in
designing novel HAdV-based vectors for gene therapy applications.
© 2008 Published by Elsevier Inc.IntroductionHAdV-based systems are currently the most common vector type
used in worldwide clinical studies. Nevertheless, systemic injection
of such vectors in many animal models results in rapid blood
clearance and high liver transduction (Alemany and Curiel, 2001). To
develop an adenoviral vector able to speciﬁcally target cancer cells,
its natural hepatic tropism must be ablated. Cell infection by HAdV-
5 involves at least two sequential virus–cell interactions. The ﬁber
knob domain of the virus initially interacts with a 46-kDa
glycoprotein termed the Coxsackie and Adenovirus Receptor (CAR)
(Bergelson et al., 1997; Tomko et al., 1997). The Arg-Gly-Asp (RGD)
sequence of the penton base then interacts with co-receptors such
as αv integrins (Wickham et al., 1993), which triggers clathrin-
coated pit endocytosis and entry into the cell (Nemerow and
Stewart, 1999).
The mechanisms that govern in vivo hepatic cell–adenovirus
interactions are not yet clear. Indeed, CAR and/or integrin-binding
ablated vectors are still able to infect the liver, suggesting that these
proteins are not the major determinants of adenoviral hepatotropism
(Nicklin et al., 2005). In addition to CAR and integrins, HAdV-5 also
utilizes a ﬁber KKTK motif to interact with HSPGs in vitro (Dechecchi
et al., 2001, 2000). HSPGs are members of the GAG (glycosaminogly-
cans) family of carbohydrates. GAGs are long polyanionic carbohydrate
chains consisting of repeating disaccharide units containing sulfatede Recherches sur le Cancer de
+33 3 20 16 92 29.
lsevier Inc.residues. GAG chains may be covalently linked to a protein to form
proteoglycans (PGs). PGs are widely expressed on the cell surface, in
intracellular secretion granules and in the extracellular matrix (Poole
et al., 1986). Evolution allowed several viruses to exploit cell-surface
HSPGs as co-receptors for attachment, including the adeno-asso-
ciated-virus-2 (Summerford and Samulski, 1998), several members of
the herpes virus family (Shukla and Spear, 2001), Flaviviruses such as
Hepatitis C (Germi et al., 2002), Dengue virus (Chen et al., 1997) and
the Sindbis virus (Byrnes and Grifﬁn, 1998).
Murine and non-human primate studies have shown a clear
hepatocyte “detargeting” when ablation of CAR and/or integrin-
binding is associated with mutations in the putative HSPG-binding
motif of the ﬁber shaft (KKTK to GAGA) (Smith et al., 2003a,b; Nicol et
al., 2004). Based on these studies, it was postulated that the direct
HAdV attachment to HSPGs is through its KKTK motif. Nevertheless, it
was recently suggested that the observed reduction in liver tropism
cannot be exclusively attributed to decreased HSPG binding after
KKTK mutation (Bayo-Puxan et al., 2006). Di Paolo revealed that the
KKTK motif within the HAdV-5 ﬁber shaft plays only a minimal, if any,
role in determining adenovirus infectivity towards hepatic cells in vivo
(Di Paolo et al., 2007). Whether the KKTK motif directly interacts with
HSPGs remains unclear.
To improve the utility of HAdV-based vectors in the context of
clinically applicable cancer gene therapy, it is essential to decrease its
hepatotropism. As HSPGs are strongly expressed on the hepatocyte
membrane surface, it is crucial to determine the exact role of HSPGs
and the KKTK motif during the HAdV infection process. Thus, we have
decided to determine the role of HSPGs in the infection process using
our CAR independent tropism chimeric vector.
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chimeric ﬁbers consisting of the N-terminal domain of HAdV-2 and
the knob domain of a bovine virus, BAdV-4 (Renaut et al., 2002, 2004).
This chimeric virus is not able to recognize the species C HAdV native
receptor hCAR, has a decreased capacity to infect the hepatic HepG2
cell line and uses a ‘lipid raft/caveolae’ endocytosis pathway to infect
cells (Rogee et al., 2007).
Here, we demonstrated that infection by HAdV-5-F2/BAdV-4 is not
mediated by HSPGs despite an intact KKTK motif. However, it appears
that some GAGs expressed on the cell surface that are not implicated
HAdV-5-F2/BAdV-4 binding are involved in its uptake. Taken together,
our data strongly suggest that HAdV-5-F2/BAdV-4 requires chondroi-
tin sulfate, particularly chondroitin sulfate C (CS-C) as a co-receptor,
and that N-glycosylation is required for infection.
Results
Implication of GAGs in HAdV-5-F2/BAdV-4 infection
We previously demonstrated that HAdV-5-F2/BAdV-4 efﬁciently
transduced the CHO cell line (Rogee et al., 2007; Renaut et al., 2004).
To explore the function of GAGs in the infection mechanism of HAdV-
5-F2/BAdV-4, we investigated its capacity to infect CHO-GAGneg in
comparison to CHO cells. The data show a reduction in the ability of
HAdV-5-F2/BAdV-4 to infect CHO-GAGneg cells in comparison to CHO
cell lines (varying from 2 fold at a concentration of 500 PP/cell
(pb0.05) to 5 fold at a concentration of 2000 PP/cell (pb0.01)) (Fig.
2A). Analyses of relative ﬂuorescence intensity (RFI) conﬁrmed this
data (data not shown).
It is possible that the O-glycosylation deﬁcit in the CHO-GAGneg
cell line could perturb another method of synthesis involved in the
effectiveness of HAdV-5-F2/BAdV-4 infection. To exclude this possi-
bility, CHO cells were treated with p-nitrophenyl-β-D-xylopyranoside,
an inhibitor of O-glycosylation (Zen et al., 2002). As a control, CHO
cells were incubated with p-nitrophenyl-α-D-xylopyranoside. A lack
of O-glycosylation-linked sugars was controlled for by detecting
sugars in glycoconjugates with an enzyme immunoassay, as described
in the Materials and methods section. For glycan detection, the
glycoprotein transferrin was used as a positive control and a non-
glycosylated protein, creatinase, was chosen as a negative control.
Inhibition of O-glycosyl chain synthesis was observed only for cells
treated with 5 mM of p-nitrophenyl-β-D-xylopyranoside (Fig. 2B).
The capacity of HAdV-2/BAdV-4 to infect CHO cells was inhibited
to 70% (pb0.01) when cells were treated with 5 mM p-nitrophenyl-β-
D-xylopyranoside in comparison to the negative control (Fig. 2C).
These results clearly indicate that GAGs are involved in the process
of HAdV-5-F2/BAdV-4 CHO infection.
GAGs are involved in HAdV-5-F2/BAdV-4 uptake into cells
The involvement of GAGs may be related to different steps in the
infection process. The ﬁrst step is the binding of the viral particles to
the plasma membrane. We next investigated this phenomenon on
CHO-GAGneg and CHO cells using FAM-labelled-HAdV-5-F2/BAdV-4.
No difference in the binding ability of the vector was observed
between CHO and CHO-GAGneg cell lines (Fig. 3A). This was conﬁrmed
by confocal microscopy. Indeed, semi-quantitative analyses of con-
focal ﬁelds (6 ﬁelds with 15 cells per ﬁeld) for each cell line were
performed. The average number of HAdV-5-F2/BAdV-4 cell-associated
aggregated-particles per confocal microscopy ﬁeld was 20 for CHO
cells and 18 for CHO-GAGneg cells (data not shown). However, the
uptake of HAdV-5-F2/BAdV-4 was less efﬁcient in CHO-GAGneg cells
(Fig. 3B) based on RFI values (1.8 fold reduction, pb0.01).
Taken together, these results suggest that HAdV-5-F2/BAdV-4 does
not used GAGs to bind to CHO cells. Nevertheless, the reduction in
transgene expression efﬁcacy resulting from a deﬁcit of xylosyltrans-ferase (Fig. 2A) combined with the decrease in HAdV-5-F2/BAdV-4
uptake in CHO-GAGneg (Fig. 3D) strongly suggests that a GAG motif is
involved in viral uptake.
Effect of heparin and of soluble HSPGs on infection efﬁciency
Xylosyltransferase enzymes participate in the formation of
chondroitin and heparan sulphate chains (Fig. 1A) (Esko et al., 1985).
GAGs include HS, chondroitin sulfate (CS) and keratan sulfate (KS). The
pathways for HS/heparin or chondroitin sulfate (CS) synthesis diverge
after the formation of this common linkage structure. The next
enzymes to act, N-acetylglucosaminyltransferase I and N-acetylgalac-
tosaminyltransferase I, directly synthesize HS/heparin or CS/DS,
respectively (Figs. 1B and C).
As heparin is often used experimentally as a HS analogue, we
tested it in an inhibition assay of viral infection. HAdV-5, which is
known to use HSPGs to bind to HeLa cells (Dechecchi et al., 2000), was
used as a positive control. Viruses weremixedwith increasing heparin
concentrations before being incubated with HeLa or CHO cells. The
infection capacity of HAdV-5was signiﬁcantly reduced in the presence
of heparin (Fig. 4A). On the other hand, HAdV-5-F2/BAdV-4-mediated
infection of CHO cells was not affected by heparin at any concentration
used (Fig. 4A).
To conﬁrm this result, the same experiment was performed in the
presence of soluble heparan sulphate (sHS). The capacity of HAdV-5 to
infect HeLa cells was also strongly reduced in the presence of sHS (Fig.
4B). However, no difference in transgene expression mediated by
HAdV-5-F2/BAdV-4 was detected (Fig. 4B), conﬁrming the results of
heparin inhibition assay (Fig. 4A).
Taken together, these results demonstrated that HS is not involved
in the infection process of HAdV-5-F2/BAdV-4.
Modulation of infectivity by enzyme treatment of cell-surface GAGs
The chondroitin sulfates are, together with heparan sulfate, the
most commonly expressed on the cell membrane. As HAdV-5-F2/
BAdV-4 does not require HS to infect CHO cells, we investigated the
role of chondroitin sulfate. We ﬁrst performed an enzymatic digestion
of chondroitin sulfates by incubating cells with either chondroitin ABC
lyase, which cleaves chondroitin sulfates A, B and C, or chondroitin
lyase C, which cleaves chondroitin sulphate C (CS-C). Treatment with
chondroitin lyase ABC decreased the capacity of viruses to infect
treated cells (50% inhibition for HAdV-5 and 76% inhibition for HAdV-
5-F2/BAdV-4) (Fig. 5A). Chondroitin lyase C had no effect on HAdV-5
infection, while a 50% reduction in the percentage of HAdV-5-F2/
BAdV-4-infected cells and reduced RFI was observed following
enzymatic removal of CS-C (Fig. 5A). The difference obtained between
treatment of cells with chondroitin ABC lyase and chondroitin lyase C
suggests that CS-A or CS-B could also play a role in CHO infection by
HAdV-5-F2/BAdV-4. To discriminate between CS-A and CS-B, we
performed competition assays in the presence of either soluble
chondroitin sulfate A (sCS-A) or soluble chondroitin sulfate B (sCS-B).
After incubation of viruses with the soluble chondroitin sulfates (A, B
or C), the mixture was added to the cells and β-galactosidase activity
was determined 24 h later. No differences in HAdV-5-F2/BAdV-4 and
HAdV-5 infection capacities were detected at all concentrations of
sCS-A used (Fig. 5B). While no difference in the percentage of positive
cells for the two viruses was observed after sCS-B incubation,
following analysis of relative ﬂuorescence intensities, we detected a
decreased infection capacity of HAdV-5 in HeLa cells in the presence of
50 μg/mL sCS-B. However, this inhibition was only observed with the
highest concentration, suggesting a non-speciﬁc afﬁnity between
HAdV-5 and sCS-B. In the same way, a reduction of the relative
ﬂuorescence intensity in CHO cells infected by HAdV-5-F2/BAdV-4
was noted for concentrations of 10 μg/mL and higher (RFI values: 35%
inhibition at 10 μg/mL to 55% inhibition at 50 μg/mL, pb0.05) (Fig. 5C
Fig. 1. Biosynthesis of proteoglycans in mammalian cells. (A) Proteoglycans are proteins containing GAG chains. GAG synthesis is initiated with the transfer of xylose from UDP-xylose
by xylotransferase to speciﬁc serine residues within the protein core. Attachment of two galactose (Gal) residues by galactosyltransferases I and II (GalTI and GalTII) and of glucuronic
acid (GlcA) by glucuronosyltransferase I (GlcATI) completes the formation of a core protein linkage tetrasaccharide. A variable sulfated repeating disaccharide unit is attached to the
core protein-linked tetrasaccharide. Different types of GAGs can be distinguished on the basis of the composition of the disaccharide repeat. (B) The disaccharide repeats of heparin
and heparan sulfate are composed of (GlcNAc+GlcA)n. (C) The disaccharide repeat of chondroitin sulfate is composed of (GalNAc+GlcA)n.
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with HAdV-5, but also only occurred with high concentrations of sCS,
suggesting a minor involvement of sCS-B in the infection process of
CHO by a chimeric vector.
To conﬁrm the data obtained after enzymatic removal of CS-C (Fig.
5A), we performed a competition assay in the presence of soluble
chondroitin sulfate C (sCS-C). No difference in transgene expression
mediated by HAdV-5-F2/BAdV-4 was detected for the percentage of
positive cells at any concentration of sCS-C used (Fig. 5D, left panel).
However, a strong reduction of RFI (from 45% at 0.5 μg/mL to 74% at
50 μg/mL of sCS-C) was observed for CHO cells infected by HAdV-5-F2/
BAdV-4, whereas the presence of sCS-C did not affect the infection
process of HAdV-5 (Fig. 5D, right panel, pb0.01).
Taken together, these results suggest that CS-C is involved in
HAdV-5-F2/BAdV-4 CHO infection.
Implication of N-glycosylation in the HAdV-5-F2/BAdV-4 infection
process
N-glycosylation is another modiﬁcation of cell-surface proteins. In
order to test the potential role of these motifs, we inhibited N-glycan
synthesis with tunicamycin (Duksin et al., 1982). Tunicamycin acts toinhibit the ﬁrst stage of the N-glycan synthesis in the endoplasmic
reticulum. We controlled for the inhibition of the N-glycosyl-linked
glycoproteins after tunicamycin treatment of CHO cells using a speciﬁc
assay, as described in the Materials and methods section. The amount
of N-glycans on CHO cells diminished in proportion to the concentra-
tion of tunicamycin used. Indeed, a strong inhibition of the synthesis
of N-glycans was observed when cells were treated with 2 μg/mL of
tunicamycin, and an almost complete inhibition was observed at a
concentration of 4 μg/mL (Fig. 6A, left panel). Moreover, the same
proﬁle was obtained after HeLa cell treatment (Fig. 6A, right panel)
suggesting that the level of N-glycans at the cell surface of these two
cell lines is comparable. CHO cells were then treated under the same
conditions, and β-galactosidase activity was determined following
HAdV-5-F2/BAdV-4 infection. Fig. 6B shows a diminished capacity of
HAdV-5-F2/BAdV-4, but not of HAdV-5, to infect CHO that was
proportional to the inhibition of N-glycan synthesis. Indeed, vector
harboring chimeric ﬁber was able to infect 100% of the cells, whereas a
84% decrease in the infection rate is observed for cells pre-treated
with 4 μg/mL tunicamycin (Fig. 6B, pb0.01).
In addition to O-glycans, the N-glycans could be involved in
different steps in the infection process. The ability of viruses to bind to
the cell surfacewas analyzed by ﬂow cytometry (Fig. 6C). Tunicamycin
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binding to treated CHO cells (20% positive cells at 0.5 μg of
tunicamycin compared to 55% positive cells when CHO cells were
not treated, pb0.01), while no effect on HAdV-5 binding to HeLa cells
was noted (Fig. 6C). These data were conﬁrmed by confocal
microscopy (data not shown).
Taken together, these results show that N-linked glycans from
glycoproteins are involved in the HAdV-5-F2/BAdV-4 CHO infection
mechanism.Whereas O-linked glycans seem to be involved only in the
uptake process of viruses (Fig. 3), N-linked glycans seem to be
involved in binding of the viral particles to the plasma membrane.
Discussion
Animal cell membranes abundantly express proteoglycans,
which are made of a protein core with one or more covalently
attached GAG chains that bind several different protein ligands.
These GAGs have been shown to be exploited by several viruses
during the attachment process to cell surfaces (for review see
Olofsson and Bergstrom, 2005). GAGs have also been shown to
mediate entry of viruses, including herpes simplex type 1 (Laquerre
et al., 1998) and human T-cell leukemia virus type 1 (Pinon et al.,
2003). HSPGs are members of the GAG family, and have beenFig. 2. Implication of GAGs in HAdV-5-F2/BAdV-4 infection. (A) CHO (■) and CHO-GAGn
concentrations of HAdV-5-F2/BAdV-4. After an additional 24 h period, β-galactosidase activit
cells (⁎pb0.05, ⁎⁎pb0.01). (B) Glycans are detected using an enzyme immunoassay after
xylopyranoside (2 and 5 mM) (upper panel) or with p-nitrophenyl-α-D-xylopyranoside (low
and non-glycosylated protein, creatinase, was used as a negative control. (C) Cells were trea
BAdV-4 for 2 h at 37 °C, the viruses were eliminated. 24 h later, β-galactosidase activity was
(⁎⁎pb0.01).described as HAdV-5 receptors able to mediate initial adenovirus
binding to cells (Dechecchi et al., 2000, 2001) and represent an
alternative entry pathway for CAR-binding ablated vector. We
previously demonstrated that HAdV-5-F2/BAdV-4 had a decreased
capacity to infect a hepatic cell line, Hep G2 (Rogee et al., 2007),
and was able to infect CHO cells that do not express CAR (Renaut
et al., 2004). The putative HSPG-binding region in the ﬁber shaft is
conserved in the chimeric ﬁber. We postulated that HSPGs may be
important in the infection process of this vector with chimeric
ﬁber. This allows us to study the potential involvement of GAGs in
the mechanism of HAdV-5-F2/BAdV-4 CHO cell attachment and
entry.
GAGs are a common type of O-glycosylation having large structural
diversity. GAGs are linear polysaccharides, composed of repeating
disaccharide units consisting of an amino sugar (N-acetyl-D-glucosa-
mine (GlcNAc) or N-acetyl-D-galactosamine (GalNAc)) and a uronic
acid (D-glucuronic acid (GlcA)) (Fig. 1A). Two different types of GAGs
can be distinguished on the basis of the disaccharide repeat
composition: (a) heparin/heparan sulfate (GlcNAc-GlcA) (Fig. 1B)
and (b) chondroitin sulfate (GalNAc-GlcA) (Fig. 1C). The ﬁrst
committed sugar transfer reaction in the assembly of GAGs is the
attachment of a xylose to a serine residue of a core protein. This
transfer reaction is done by a xylosyltransferase (Prihar et al., 1980)eg (□) cells were incubated for 2 h at 37 °C in serum-free medium with increasing
y was evaluated by ﬂow cytometry. The results are expressed as a percentage of positive
incubation of 5×105 CHO cells with increasing concentrations of p-nitrophenyl-β-D-
er panel) overnight at 37 °C. A glycoprotein, transferrin, was used as a positive control,
ted as described in part B and rinsed. After incubation with 2000 PP/cell of HAdV-5-F2/
measured by ﬂow cytometry. The results are expressed as a percentage of positive cells
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not produce detectable levels of GAGs (Esko et al., 1985).
In this study, mutant CHO-derived cells lacking all GAGs (CHO-
GAGneg) were shown to be less sensitive to HAdV-5-F2/BAdV-4
infection compared to wild-type CHO cells, indicating that GAGs are
involved in CHO infection by this chimeric vector (Fig. 2A). These
data were conﬁrmed by using an inhibitor of O-linked glycan
synthesis. Again, the capacity of HAdV-5-F2/BAdV-4 to infect CHO
cells was dramatically reduced by 70% after pre-treatment with the
O-linked glycan synthesis inhibitor p-nitrophenyl-β-D-xylopyrano-
side (Fig. 2C). Interestingly, HAdV-5-F2/BAdV-4 binding occurred
with a similar efﬁciency in both CHO and CHO-GAGneg cells,
suggesting that O-linked glycans were not involved in virus–cell
interactions (Fig. 3A). However, uptake assays revealed a reduction
in HAdV-5-F2/BAdV-4 internalization in CHO-GAGneg (Fig. 3B). We
can thus speculate that protein(s) with O-linked glycans play a role
as co-receptors for HAdV-5-F2/BAdV-4 in the CHO infection process,
similar to integrins for HAdV-5 (Wickham et al., 1993). Indeed,
several studies have demonstrated that HSPGs themselves can
mediate uptake of several ligands, including growth factors and
lipoproteins (Reiland and Rapraeger, 1993; Williams and Fuki, 1997),
and are co-receptors for several pathogenic microorganisms
(Rostand and Esko, 1997), including herpes simplex virus type 1
(HSV-1) (WuDunn and Spear, 1989).
The data concerning the role of the KKTK motif in liver cell
infection by HAdV-5 is controversial. Several studies demonstrated
that HAdV-5 viruses harboring mutations in both the CAR-binding
motif and the putative HSPG-binding region show strikingly
reduced hepatic tropism in various animal models followingFig. 3. GAG involvement in HAdV-5-F2/BAdV-4 uptake. (A) 106 CHO (■) or CHO-GAGneg
(□) cells were incubated with 1011 PP/mL of FAM-labelled-HAdV-5-F2/BAdV-4 in 1% of
PBS/BSA for 90 min at 4 °C. Cells were rinsed and viral binding was analyzed by ﬂow
cytometry. The results are expressed as relative ﬂuorescence intensity (RFI) (NS: not
signiﬁcant). (B) To determine uptake, cells were treated as described before, except that
after incubation at 4 °C, an incubation period of 30 min at 37 °C was performed. Cells
were rinsed with trypsin to remove the non-internalized particles, and uptake of FAM-
labelled-HAdV-5-F2/BAdV-4 was quantiﬁed using ﬂow cytometry and the results are
expressed as relative ﬂuorescence intensity (RFI) (⁎⁎pb0.01).
Fig. 4. Effect of heparin and soluble HSPGs on viral infection. HAdV-5 or HAdV-5-F2/
BAdV-4 was preincubated with either heparin (A) or soluble HSPGs (B) at the indicated
concentrations for 2 h at 4 °C. Both vectors were then added to HeLa or CHO cells. After
24 h at 37 °C, β-galactosidase activitywas determined by ﬂowcytometry. The results are
expressed as a percentage of positive cells (NS: not signiﬁcant; ⁎pb0.05, ⁎⁎pb0.01).intravenous delivery (Smith et al., 2003a, 2003b; Nicol et al.,
2004). However, recent studies revealed that the proposed direct
interactions between the KKTK ﬁber shaft motif and hepatic HSPGs
are unlikely to be the mechanism of efﬁcient liver cell infection by
HAdVs when virus is delivered intravenously (Di Paolo et al., 2007).
It has been suggested that mutations in the KKTK motif induce an
alteration in the post-internalization step of the adenoviral vectors
(Kritz et al., 2007).
Our competition assays revealed that HSPGs are not involved in
the infection process of chimeric vectors (Fig. 4) despite the fact that
the KKTK motif is not mutated in the chimeric ﬁber. We can then
speculate that modiﬁcations realized in the adenoviral ﬁber
sequence lead to conformational changes or steric interferences
that inhibit the interaction with HSPGs. Our data are consistent with
the results of Bayo-Puxan showing that the KKTK motif is important
for the stability and ﬂexibility of the ﬁber. They explained that the
reduction in hepatotropism previously observed with KKTK-mutated
adenovirus was primarily the result of an alteration of the ﬁber
structure, and not decreased binding with HSPGs (Bayo-Puxan et al.,
2006). Our data suggest that the adenoviral ﬁber KKTK motif does
not directly interact with HSPGs. It was demonstrated that
coagulation factors IX, X and component C4-binding protein
(C4BP) play a major role in hepatocytes and Kupffer cells' uptake
of intravenous injected-HAdVs. These analyses demonstrated that
these blood factors mediate in vivo tropism by ‘cross-linking’ HAdVs
to the hepatocellular HSPG and to the low-density lipoprotein LDL-
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2007; Parker et al., 2006, 2007; Shayakhmetov et al., 2005).
Waddington et al. reveal that, contrary to FIX which binds to the
adenoviral ﬁber knob, FX interacts with the hexon hypervariable
regions (HVRs) (Waddington et al., 2008).
Nevertheless, the results obtained from CHO-GAGneg cells indicate
that GAGs could be co-receptors for the chimeric vector. CHO-GAGneg
cells are deﬁcient in the production of all GAGs, including HS, CS and
KS. It has been demonstrated that cell-surface CS is a co-receptor for
binding of herpes simplex virus to cells (Bergefall et al., 2005), and
some studies clearly indicate that chondroitin sulfate moieties on cell-
associated CSPGs represent a major component for viral entry and
replication of HIV-1 (Argyris et al., 2003). Here, we demonstrated that
chondroitin sulfate chain type C is involved in HAdV-5-F2/BAdV-4
entry into CHO cells (Figs. 5A, D).Fig. 5.Modulation of infectivity after enzyme treatment of cell-surface GAGs. (A) CHO or He
ABC lyase (white box) or chondroitin lyase C (hatched box). Cells were thenwashed with PBS
cells. β-galactosidase activity was measured by ﬂow cytometry 24 h later. The results are exp
(RFI, right panel) (⁎pb0.05; ⁎⁎pb0.01). Parental or modiﬁed vectors were preincubated with
the indicated concentrations for 2 h at 4 °C. HAdV-5 and HAdV-5-F2/BAdV-4 (2000 PP/cell) w
activity was determined by ﬂow cytometry. The results are expressed as a percentage of po
⁎⁎pb0.01)We also demonstrated that chondroitin sulfate chain type B plays a
minor role in HAdV-5-F2/BAdV-4 infection of CHO cells (Fig. 5C).
However, the decrease in infection capacity with CS-B was observed
only at high concentrations and can be explained by a non-speciﬁc
afﬁnity between the virus and sCS-B.
It is important to note that HSPGs are highly expressed on the
hepatocyte membrane surface, as opposed to chondroitin sulfate,
which is detected predominantly in the vessel walls of veins, in the
adventitial layer of arteries, in the walls of the bile ducts and in the
interstitial connective tissue of the periportal tract (Voss et al., 1986).
This GAG distribution could modify the biodistribution of HAdV-5-F2/
BAdV-4 in vivo, and particularly in the liver. It would be of interest to
determine the impact of chondroitin sulfate C as co-receptor on the
distribution of the virus in organs in vivo. However, data presented
here have beenperformedusing cells that are not derived from liver. ToLa cells were incubated (black box) for 90 min at 37 °C with either 10 U/mL chondroitin
and incubatedwith 2000 PP/mL of HAdV-5 for HeLa cells or HAdV-5-F2/BAdV-4 for CHO
ressed as a percentage of positive cells (left panel) and as Relative Fluorescence Intensity
either chondroitin sulfate A (B), chondroitin sulfate B (C) or chondroitin sulfate C (D) at
ere then added to HeLa and CHO cells, respectively. After 24 h at 37 °C, β-galactosidase
sitive cells (left panels) and as Relative Fluorescence Intensity (right panels). (⁎pb0.05;
66 S. Rogée et al. / Virology 380 (2008) 60–68be more relevant regarding the liver tropism, HAdV-5-F2/BAdV-4
biodistribution in vivo after intravenous injection are now in progress
in our laboratories (manuscript in progress).
Tunicamycin treatments revealed a critical role for N-linked
glycosylation in the infection mechanism of HAdV-5-F2/BAdV-4 in
CHO cells. Indeed, we observed a strong reduction in reporter gene
expression in CHO cells treated with tunicamycin (Fig. 6B). This
reductionwas associated with reduced HAdV-5-F2/BAdV-4 binding as
demonstrated using cytometric analyses (Fig. 6C) and confocal
microscopy (data not shown). We can therefore speculate that
inhibition of HAdV-5-F2/BAdV-4 receptor glycosylation by tunicamy-
cin may block normal folding, leading to retention and degradation in
the endoplasmic reticulum; this would subsequently lead to a
reduction in the capacity of HAdV-5-F2/BAdV-4 to bind the CHO
cells. Indeed, N-linked glycosylation is critical in some cases for
normal folding of proteins in the endoplasmic reticulum (Helenius,
1994), and N-linked glycosylation can be required for cell membrane
protein translocation (Fan et al., 1997). Further studies are now
required ﬁrst to identify the HAdV-5-F2/BAdV-4 receptor, and then to
answer questions concerning the speciﬁc role of N-glycosylation in
the biosynthesis and trafﬁcking of this receptor.
In summary, we demonstrated that engineering the ﬁber without
any mutation in the KKTK motif on the ﬁber alters HSPG binding,
probably due to a ﬁber structuremodiﬁcation. The results of our study,
as well as those of others, suggest that the KKTK motif is not directly
involved in the interaction with HSPGs. Thus, mutation of KKTK motif
is not necessary to reduce hepatotropism since a modiﬁcation
performed in the adenoviral ﬁber could change the conformational
structure. In the future, to de-target the liver, itwill bemore interesting
to consider the conformational change of the ﬁber than to abolish the
interaction between the adenovirus and the cells.Fig. 6. Implication of N-glycans in the HAdV-5-F2/BAdV-4 infection process. (A) Cells (CHO
glycans were detected by an enzyme assay. Transferrinwas used as a positive control and cre
or 4 μg/mL) overnight at 37 °C. Cells were then rinsed and infected by 2000 PP/cell of eith
eliminate viruses 2 h post-infection, and β-galactosidase activity was quantiﬁed by ﬂow cyt
⁎⁎pb0.01). (C) Cells were incubated with tunicamycin (0.5, 1, 2 or 4 μg/mL) overnight at 37 °C
F2/BAdV-4 or -HAdV-5 in 1% of PBS/BSA for 90 min at 4 °C. Cells were rinsed, and viral binMaterials and methods
Cell culture
CHO-GAGneg cell lines were kindly provided by Dr. L. Tenen-
baum (ULB, Bruxelle). CHO (Chinese Hamster Ovary), CHO-GAGneg
and HeLa cell lines were cultured in Dulbecco's medium supple-
mented with 10% fetal bovine serum (FBS), 1% penicillin and
streptomycin and 1% non-essential amino acids. Cells were
maintained in a humidiﬁed incubator with 5% CO2 and were
passaged twice a week.
Adenovirus ampliﬁcation and labeling
Recombinant HAdV-5 or HAdV-5-F2/BAdV-4, E1 deleted vectors
containing a β-galactosidase reporter gene under the control of the
immediate early CMV promoter were constructed, ampliﬁed and
puriﬁed in our laboratory as previously described (Renaut et al., 2002,
2004). The conjugation of the carboxyﬂuorescein succinimidyl ester to
adenoviral proteins was performed as previously described (Colin et
al., 2004).
HAdV infection
Adherent cells were seeded in 6-well culture plates at a density of
1.5×106 cells per well. Cells were then infected with various amounts
of HAdV-5 or HAdV-5-F2/BAdV-4 vectors for 2 h at 37 °C in serum-free
medium.Medium containing 4% FBSwas added following infection for
24 h at 37 °C. The β-galactosidase activity was determined using
ﬂuorescein-β-D-galactopyranoside, as previously described (Renaut et
al., 2004; Rogee et al., 2007).and HeLa) were pre-treated with tunicamycin (1, 2 or 4 μg/mL) overnight at 37 °C. The
atine was used as a negative control. (B) Cells were incubated with tunicamycin (0.5, 1, 2
er HAdV-5-F2/BAdV-4 for CHO cells or HAdV-5 for HeLa cells. The cells were rinsed to
ometry 24 h later. The results are expressed as a percentage of positive cells (⁎pb0.05;
. Cells were then rinsed, and were incubated with 1011 PP/mL of FAM-labelled-HAdV-5-
ding was analyzed by ﬂow cytometry (⁎⁎pb0.01).
67S. Rogée et al. / Virology 380 (2008) 60–68For competition assays, viruses were preincubated with either
heparin (from porcine intestine; Sigma), soluble HSPGs (Sigma),
soluble Chondroitin Sulfate A (Sigma), soluble Chondroitin Sulfate B
(Sigma) or soluble Chondroitin Sulfate C (MP Biolab) in PBS for 2 h at
4 °C. The mixture was added to the cells and allowed to incubate for
24 h at 37 °C, after which the β-galactosidase activity was determined.
Confocal microscopy
For confocal microscopy analysis, cells (3×105) were plated by
cytospin for 5 min at 55 g and then ﬁxed with 2% PFA for 20 min at
room temperature (RT). After one rinse with 50 mM NH4Cl, cells were
treated for 15 min at RT with 1 mg/mL RNase A. Nuclei were labeled
with TOPRO-3 (1.5 μM for 30 min at 37 °C) and the preparation was
mounted in Vectashield (Abcys). Confocal microscopy was performed
using a TCS SP Leica (Lasertechnichk GmbH) microscope.
Binding assays for HAdVs
For binding assays, 1.5×106 cells were incubated in suspension for
1 h in 100 μL of DMEM containing 1011 physical particles (PP)/mL of
FAM-labeled-HAdV-5 or -HAdV-5-F2/BAdV-4 in serum-free medium
at 4 °C. The number of PP was determined based on the DNA
absorbance at 260 nm. Cells were then rinsed once in 1% PBS/BSA and
ﬁxed with 1% PFA for 20 min at RT. The efﬁciency of binding was
quantiﬁed using either ﬂuorescence ﬂow-cytometry analysis or
confocal microscopy, as described above.
Removal of GAGs from cell membrane
To remove GAGs from the cell surface, cells were incubated for
90 min at 37 °C with either 10 U/mL of chondroitin ABC lyase (Sigma)
or Chondroitin lyase C (Sigma). Cells were then washed with PBS and
processed for infection or binding assays as described above.
Inhibition of O-glycan synthesis
Cells (5×105) were incubated with various concentrations of p-
nitrophenyl-β-D-xylopyranoside (2 and 5 mM) overnight at 37 °C. As a
control, cells were incubated in the presence or absence of p-
nitrophenyl-α-D-xylopyranoside. Cells were rinsed and infected
with 2000 PP/cell of HAdV-5-F2/BAdV-4 for 2 h at 37 °C. The virus
was then eliminated and cells were rinsed. After 24 h, β-galactosidase
activity was measured by ﬂow cytometry using ﬂuorescein-β-D-
galactopyranoside as previously described (Rogee et al., 2007).
Tunicamycin treatment
CHO and HeLa cells were cultured in DMEM supplemented with or
without various concentrations of tunicamycin (0.5, 1, 2 and 4 μg/mL)
overnight at 37 °C. Cells were then rinsed twice with DMEM, and
viruses were added at a concentration of 2000 PP/cell for 2 h at 37 °C
in serum-free medium. Cells were rinsed twice with DMEM to remove
unbound virus. Medium containing 4% FBS was added to the cells for a
further post-infection period of 24 h at 37 °C. The β-galactosidase
activity was determined by ﬂow cytometry using ﬂuorescein-β-D-
galactopyranoside as previously described (Rogee et al., 2007).
DIG glycan detection
The proteins from treated or non-treated cells were extracted,
and 50 μg protein per sample were separated by SDS-PAGE and
transferred onto a nitrocellulose membrane. For detection of sugars
in glycoconjugates, an enzyme immunoassay (DIG Glycan detection
kit, Roche) was used. The glycoproteins were oxidized with 10 mM
sodium metaperiodate in sodium acetate buffer at pH 5.5 for 20 minat RT. The membrane was then incubated with 1 μL of DIG-0-3-
succinyl-ε-aminocaproic acid hydrazide dissolved in 5 mL sodium
acetate buffer pH 5.5 for 1 h at RT. Next, the membrane was
incubated with blocking solution overnight at 4 °C, after which the
blots were incubated with anti-digoxigenin-AP (1/100) for 1 h.
Digoxigenin-labeled glycoproteins were detected using a staining
solution (10 mL Tris buffer pH 9.5, 200 μL NTB (4-nitro blue
tetrazolium chloride)/5-bromo-4-chloro-3-indolyl-phosphate).
Statistical analysis
All data are shown as the mean±SEM. All in vitro experiments
were performed in duplicate from three independent tests with at
least two different virus preparations. The Mann–Whitney test was
used to calculate statistical signiﬁcance.
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